Your browser doesn't support javascript.
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.
Abhyankar, Mayuresh M; Mann, Barbara J; Sturek, Jeffrey M; Brovero, Savannah; Moreau, G Brett; Sengar, Anjali; Richardson, Crystal M; Agah, Sayeh; Pomés, Anna; Kasson, Peter M; Tomai, Mark A; Fox, Christopher B; Petri, William A.
  • Abhyankar MM; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
  • Mann BJ; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
  • Sturek JM; Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, 22903, USA.
  • Brovero S; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
  • Moreau GB; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
  • Sengar A; Departments of Molecular Physiology and Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
  • Richardson CM; INDOOR Biotechnologies, Inc., Charlottesville, VA, 22903, USA.
  • Agah S; INDOOR Biotechnologies, Inc., Charlottesville, VA, 22903, USA.
  • Pomés A; INDOOR Biotechnologies, Inc., Charlottesville, VA, 22903, USA.
  • Kasson PM; Departments of Molecular Physiology and Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.
  • Tomai MA; 3M Corporate Research and Materials Lab, 3M Center, 270-4N-04, St Paul, MN, 55144, USA.
  • Fox CB; Infectious Disease Research Institute, Seattle, WA, 98102, USA.
  • Petri WA; Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA. wap3g@virginia.edu.
NPJ Vaccines ; 6(1): 137, 2021 Nov 18.
Article in English | MEDLINE | ID: covidwho-1526080
ABSTRACT
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00399-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00399-0